Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.89
+3.7%
$0.88
$0.70
$1.65
$66.37M2.11342,362 shs129,515 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$8.55
+3.5%
$5.93
$3.99
$9.87
$388.58M2.22924,270 shs1.58 million shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.37
+7.9%
$1.48
$1.02
$9.69
$77.53M1.06360,846 shs317,881 shs
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$2.55
-8.9%
$1.73
$0.13
$3.50
$192.68M0.04841,921 shs1.57 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
+4.46%+0.34%+16.42%-16.78%-28.76%
LifeMD, Inc. stock logo
LFMD
LifeMD
+3.51%+13.40%+69.98%+30.53%-8.26%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+6.61%-8.67%+10.48%-34.13%-82.28%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-8.93%-3.77%+42.46%+155.00%+174.19%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
2.1558 of 5 stars
3.53.00.00.02.41.70.0
LifeMD, Inc. stock logo
LFMD
LifeMD
2.5593 of 5 stars
3.53.00.00.02.61.70.6
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.4006 of 5 stars
4.54.00.00.01.81.70.6
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
0.5401 of 5 stars
0.03.00.00.02.51.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3.00
Buy$5.25489.56% Upside
LifeMD, Inc. stock logo
LFMD
LifeMD
3.00
Buy$11.0028.65% Upside
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$8.50520.44% Upside
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TOI, LFMD, TCRX, and CLSD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $10.00
5/6/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
4/30/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/8/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
4/8/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/31/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
3/28/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
3/28/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $4.00
3/14/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$10.00
3/12/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $14.00
3/11/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$1.66M41.36N/AN/A($0.25) per share-3.56
LifeMD, Inc. stock logo
LFMD
LifeMD
$234.01M1.66N/AN/A$0.15 per share57.00
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$4.42M17.54N/AN/A$3.15 per share0.43
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$393.41M0.49N/AN/A$0.77 per share3.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$32.49M-$0.47N/AN/AN/A-413.83%N/A-92.90%N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
-$20.60M-$0.34N/A71.25N/A-12.06%N/A-36.34%N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$89.22M-$1.09N/AN/AN/A-1,188.88%-58.72%-36.02%N/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$83.07M-$0.71N/AN/A-17.63%-186.83%-34.58%5/14/2025 (Estimated)

Latest TOI, LFMD, TCRX, and CLSD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million
5/6/2025Q1 2025
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04$0.01+$0.05$0.01$62.47 million$65.70 million
3/27/2025Q4 2024
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$0.13-$0.10+$0.03-$0.10$0.27 million$0.31 million
3/24/2025Q4 2024
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$0.08-$0.14-$0.06-$0.14$109.15 million$100.27 million
3/10/2025Q4 2024
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04-$0.02+$0.02-$0.02$57.43 million$64.26 million
3/5/2025Q4 2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.27-$0.29-$0.02-$0.30$1.43 million$0.67 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
4.49
4.49
LifeMD, Inc. stock logo
LFMD
LifeMD
N/A
0.83
0.78
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.13
9.56
9.56
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
5.91
2.49
2.27

Institutional Ownership

CompanyInstitutional Ownership
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
36.86%

Insider Ownership

CompanyInsider Ownership
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
9.20%
LifeMD, Inc. stock logo
LFMD
LifeMD
15.97%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
2.76%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
8.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3077.28 million68.87 millionOptionable
LifeMD, Inc. stock logo
LFMD
LifeMD
23045.45 million36.40 millionOptionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million51.90 millionNot Optionable
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
66075.56 million68.38 millionNot Optionable

Recent News About These Companies

Q4 2024 Oncology Institute Inc Earnings Call
The Oncology Institute announces $16.5M private placement

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clearside Biomedical stock logo

Clearside Biomedical NASDAQ:CLSD

$0.89 +0.03 (+3.69%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$0.90 +0.01 (+1.07%)
As of 07:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

LifeMD stock logo

LifeMD NASDAQ:LFMD

$8.55 +0.29 (+3.51%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$8.65 +0.10 (+1.17%)
As of 07:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.37 +0.10 (+7.87%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$1.36 -0.01 (-0.36%)
As of 07:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Oncology Institute stock logo

Oncology Institute NASDAQ:TOI

$2.55 -0.25 (-8.93%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$2.55 +0.00 (+0.16%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.